sever
acut
respiratori
syndrom
sar
caus
sarsassoci
coronaviru
sarscov
caus
worldwid
outbreak
chapter
start
descript
pathogenesi
diseas
follow
review
variou
pharmacolog
treatment
support
ventilatori
strategi
adopt
outbreak
principl
use
design
variou
combin
therapeut
agent
treatment
modal
also
describ
base
present
knowledg
sar
postul
caus
threephas
ill
first
viral
replic
phase
associ
increas
viral
load
result
host
reaction
form
fever
system
symptom
symptom
may
improv
subsid
patient
second
phase
immunopatholog
damag
occur
major
reflect
pulmonari
manifest
vari
degre
clinic
sever
day
symptom
onset
phase
correspond
peak
viral
load
follow
fall
subsequ
onset
igg
seroconvers
character
recrudesc
fever
oxygen
desatur
radiolog
progress
pneumon
well
intens
macrophag
activ
lung
patient
may
develop
acut
respiratori
distress
syndrom
ard
stage
final
phase
pulmonari
destruct
proport
case
especi
overexuber
host
respons
second
immunopatholog
phase
remain
uncontrol
consensu
type
pharmacolog
therapi
may
effect
sar
gener
sinc
definit
laboratori
diagnosi
sar
may
made
day
symptom
onset
empir
antibiot
still
indic
presenc
pulmonari
infiltr
antivir
immunomodulatori
agent
also
use
empir
outbreak
also
review
chapter
although
activ
sarscov
antibiot
prescrib
physician
sar
patient
initi
present
microbiolog
confirm
obtain
antibiot
chosen
cover
typic
atyp
organ
accord
publish
treatment
guidelin
communityacquir
pneumonia
cap
coinfect
organ
may
may
benefit
antibiot
uncommon
last
outbreak
includ
metapneumoviru
chlamydialik
agent
influenza
viru
parvoviru
amoxicillinclavulan
clarithromycin
levofloxacin
alon
often
use
initi
treatment
broader
spectrum
antibiot
may
use
presenc
sever
cap
wherea
potent
antipseudomon
antibiot
like
piperacillintazobactam
imipenamcilastatin
cefoperazonesulbactam
reserv
potenti
complic
superimpos
sepsi
may
expect
corticosteroid
use
mechan
ventil
institut
centr
recommend
earli
use
potent
broad
spectrum
antibiot
coverag
ceftriaxon
cefipim
levofloxacin
treat
andor
prevent
possibl
underli
bacteri
infect
may
associ
earli
use
puls
dose
corticosteroid
sar
broadspectrum
antivir
activ
mani
dna
rna
virus
nucleosid
analogu
chosen
empir
treatment
earli
outbreak
even
sarscov
identifi
subsequ
clinic
experi
show
ribavirin
appear
signific
effect
clinic
cours
term
fever
subsid
improv
oxygen
satur
clear
chest
radiograph
shadow
use
ribavirin
howev
continu
centr
better
antivir
agent
avail
report
suggest
despit
weak
viral
inhibitori
activ
appear
possess
immunomodulatori
effect
treatment
mous
coronaviru
hepat
mediat
inhibit
induct
macrophag
proinflammatori
cytokin
cytokin
preserv
cytokin
monitor
quantit
revers
transcriptas
polymeras
chain
reaction
rtpcr
nasopharyng
aspir
could
howev
demonstr
antivir
effect
vivo
subsequ
also
found
ribavirin
slight
vitro
activ
sarscov
inhibitori
dosag
may
achiev
clinic
teratogen
effect
doubl
contracept
seven
month
must
practis
cessat
ribavirin
therapi
side
effect
dose
relat
common
elderli
includ
haemolyt
anemia
elev
transaminas
level
bradycardia
health
canada
stop
use
ribavirin
sar
hong
kong
plan
test
drug
random
control
trial
togeth
kaletra
anoth
outbreak
among
variou
antivir
drug
screen
lopinavirritonavir
coformul
kaletra
abbott
laboratori
usa
found
activ
prototyp
sarscov
vitro
lopinavir
compon
activ
sarscov
ritonavir
inhibit
metabol
lopinavir
increas
serum
concentr
lopinavir
inhibit
coronavir
proteas
block
process
viral
replicas
polyprotein
thu
prevent
replic
viral
rna
synerg
also
demonstr
lopinavir
ribavirin
use
combin
retrospect
match
cohort
studi
hong
kong
sar
outbreak
area
experi
drug
patient
given
kaletra
lopinavir
mgritonavir
mg
oral
everi
hour
ribavirin
corticosteroid
divid
two
subgroup
analysi
fortyfour
patient
kaletra
given
initi
treatment
day
median
symptom
onset
compar
match
cohort
receiv
ribavirin
corticosteroid
kaletra
group
show
reduct
overal
death
rate
intub
rate
lower
requir
puls
methylprednisolon
rescu
patient
receiv
kaletra
later
cours
ill
rescu
therapi
follow
poor
respons
ribavirin
corticosteroid
benefit
seen
anoth
hong
kong
studi
sar
patient
treat
combin
kaletra
ribavirin
corticosteroid
compar
match
histor
control
given
ribavirin
corticosteroid
lower
incid
advers
clinic
outcom
term
ard
death
day
symptom
onset
seen
kaletra
group
find
two
studi
suggest
kaletra
combin
ribavirin
may
effect
antivir
agent
sar
case
earli
use
kaletra
may
decreas
initi
viral
load
viral
replic
phase
henc
amelior
subsequ
immunopatholog
lung
damag
base
retrospect
data
kaletra
studi
combin
ribavirin
random
control
trial
plan
futur
sar
treatment
hong
kong
interferon
belong
group
cytokin
control
cellular
immun
respons
antivir
activ
mediat
direct
effect
infect
cell
modul
host
immun
respons
vitro
test
three
recombin
interferon
sarscov
show
interferon
ifn
potent
prophylaxi
antivir
agent
infect
anoth
studi
report
complet
inhibit
cytopath
effect
sarscov
cultur
ifn
subtyp
human
leukocyt
similar
activ
also
report
third
vitro
studi
therapeut
dosag
shown
effect
accept
monkey
use
treatment
sar
china
canada
openlabel
uncontrol
canadian
studi
patient
treat
corticosteroid
alon
initi
treatment
compar
nine
given
corticosteroid
plu
ifn
infergen
intermun
inc
brisban
ca
usa
latter
group
show
shorter
time
resolut
radiograph
abnorm
lung
better
oxygen
satur
earlier
cessat
supplement
oxygen
decreas
elev
creatin
kinas
level
base
vitro
vivo
data
select
interferon
either
alon
combin
antivir
drug
appear
show
promis
treatment
efficaci
human
corticosteroid
patient
enter
immunopatholog
phase
intens
macrophag
cytokin
activ
occur
lung
result
sever
pneumon
respiratori
failur
immunomodulatori
agent
usual
given
control
overexuber
host
respons
corticosteroid
commonli
use
purpos
outbreak
differ
seri
report
differ
method
corticosteroid
prescript
treatment
start
demonstr
respons
antibiot
soon
epidemiolog
histori
contact
sar
could
establish
base
set
surrog
clinic
marker
may
reflect
overreact
host
respons
divers
regard
rout
administr
dosag
type
prednisolon
methylprednisolon
hydrocortison
dexamethason
corticosteroid
use
well
durat
administr
conclus
efficaci
drug
difficult
reach
moreov
sever
diseas
may
prompt
use
higher
dosag
corticosteroid
make
relationship
efficaci
corticosteroid
use
obtain
retrospect
analysi
straightforward
base
present
knowledg
diseas
appear
logic
immunomodulatori
agent
like
corticosteroid
avoid
earli
phase
viral
replic
hand
consid
sign
suggest
overreact
host
respons
may
reflect
clinic
radiograph
deterior
benefici
result
may
depend
administr
adequ
initi
corticosteroid
dosag
long
enough
dampen
overact
immun
respons
avoid
rebound
overimmunosuppress
initi
steroid
dosag
rang
oral
prednisolon
mgkgday
high
puls
methylprednisolon
mg
intraven
daili
day
retrospect
data
suggest
higher
dose
given
two
three
week
sever
case
benefit
although
good
respond
develop
recurr
respiratori
failur
initi
respons
well
poor
respond
puls
corticosteroid
form
methylprednisolon
g
two
day
may
effect
rescu
therapi
corticosteroid
must
use
cautious
side
effect
common
addit
hospitalacquir
infect
associ
compar
advers
outcom
patient
requir
mechan
ventil
postsar
avascular
necrosi
hip
knee
common
order
fibrin
thrombi
found
small
pulmonari
arteri
autopsi
studi
togeth
initi
swell
pulmonari
vessel
moreov
system
vascul
includ
oedema
localis
fibrinoid
necrosi
infiltr
lymphocyt
monocyt
plasma
cell
vessel
wall
heart
lung
liver
kidney
adren
stroma
striat
muscl
well
thrombosi
small
vein
seen
three
sar
case
guangzhou
china
sarscov
may
thu
deleteri
effect
endothelium
predispos
small
vessel
thrombosi
addit
patient
diagnos
suffer
osteonecrosi
primarili
hip
found
suffer
one
primari
coagul
disord
includ
initi
diagnos
idiopath
avascular
necrosi
coagul
disord
includ
thrombophilia
hypofibrinolysi
analys
requir
clarifi
whether
avascular
necrosi
due
corticosteroid
underli
coagul
abnorm
sarscov
infect
per
se
group
first
develop
standard
treatment
protocol
midmarch
earli
sar
outbreak
hong
kong
sarscov
identifi
protocol
allow
commenc
high
puls
dose
methylprednisolon
worsen
clinic
radiograph
paramet
trial
antibiot
subsequ
taper
next
three
week
satisfactori
respons
standard
protocol
eventu
appli
total
consecut
admit
sar
patient
mean
age
year
laboratoryconfirm
sar
overal
mortal
observ
three
death
occur
patient
age
year
multicentr
studi
compar
four
treatment
regimen
guangzhou
china
also
found
high
dosag
corticosteroid
adjust
accord
clinic
radiolog
sever
produc
zero
mortal
clinicallydefin
sar
patient
mean
age
year
figur
compar
favour
estim
case
fatal
rate
patient
year
old
patient
year
old
human
gamma
immunoglobulin
use
treat
sar
patient
poor
respons
corticosteroid
pentaglobin
pentaglobin
biotest
pharma
gmbh
dreieich
germani
igmenrich
immunoglobulin
product
tri
hong
kong
hospit
mainland
china
pentaglobin
given
mgkgday
three
consecut
day
patient
deterior
despit
ribavirin
repeat
rescu
methylprednisolon
improv
radiograph
score
oxygen
requir
note
singaporean
seri
methylprednisolon
combin
highdos
intraven
immunoglobulin
gkg
administ
daili
three
consecut
day
critic
ill
probabl
sar
patient
acut
lung
injuri
ard
compar
patient
given
immunoglobulin
lower
mortal
trend
toward
earlier
recoveri
found
random
control
trial
larger
patient
group
requir
confirm
efficaci
immunoglobulin
convalesc
plasma
use
sever
centr
hong
kong
sever
case
appar
respond
treatment
plasma
taken
sar
patient
convalesc
reinfus
sick
patient
ml
aliquot
daili
day
believ
neutral
immunoglobulin
convalesc
plasma
may
abl
decreas
viral
load
earli
infus
report
provid
clinic
benefit
mani
drug
tri
consid
desper
outbreak
includ
thymosin
alpha
zadaxin
sciclon
pharmaceut
inc
san
carlo
ca
usa
tumour
necrosi
factor
block
agent
name
etanercept
enbrel
immunex
corp
seattl
wa
usa
infliximab
remicad
centocor
inc
malvem
pa
usa
compound
includ
cyclophosphamid
azathioprin
cyclosporin
thalidomid
tradit
chines
herbal
medicin
use
western
medicin
treat
sar
good
result
report
centr
mainland
china
compar
use
western
medicin
alon
shorter
time
symptom
improv
fever
subsid
shorter
durat
hospit
corticosteroid
use
seen
herbal
medicin
tradit
use
combin
difficult
dissect
efficaci
individu
agent
glycyrrhizin
activ
compon
deriv
liquoric
root
found
effect
sarscov
vitro
administ
either
viral
adsorpt
period
sinc
effect
high
concentr
howev
clinic
util
remain
uncertain
anoth
herb
call
baicalin
also
demonstr
antisarscov
activ
unpublish
data
despit
treatment
effort
mani
sar
patient
still
develop
acut
hypoxem
respiratori
failur
overal
requir
intens
care
unit
icu
high
depend
care
develop
ard
initi
manag
sarsrel
respiratori
failur
oxygen
supplement
assist
ventil
noninvas
invas
mean
consid
hypoxaemia
dyspnoea
persist
noninvas
ventil
niv
deliv
continu
posit
airway
pressur
cpap
bilevel
pressur
support
tightfit
facial
nasal
mask
commonli
employ
mani
chines
hospit
centr
hong
kong
advantag
niv
includ
rapid
improv
vital
sign
oxygen
tachypnoea
especi
appli
earli
reduct
need
increas
dosag
corticosteroid
treat
progress
respiratori
failur
avoid
intub
invas
ventil
twothird
critic
ill
sar
patient
reduct
infect
risk
patient
reduct
mechan
ventil
requir
henc
ventilatorassoci
pneumonia
may
aggrav
use
corticosteroid
reduct
risk
healthcar
worker
obviat
need
potenti
highli
infecti
procedur
intub
sinc
patient
respond
niv
usual
within
hour
nonrespond
eventu
need
endotrach
intub
identifi
earli
cpap
cm
h
bilevel
pressur
support
inspiratori
posit
airway
pressur
ipap
cm
h
expiratori
posit
airway
pressur
epap
cm
h
reason
start
pressur
lower
pressur
safer
start
high
frequenc
spontan
pneumomediastinum
subcutan
emphysema
would
natur
aggrav
posit
pressur
ventil
form
centr
appli
niv
patient
persist
sarsrel
acut
respiratori
failur
mean
age
coronaviru
serolog
posit
niv
start
day
mean
symptom
onset
mean
durat
usag
hour
endotrach
intub
avoid
patient
icu
stay
could
shorten
significantli
day
vs
day
intub
case
chest
radiographi
score
within
first
hour
niv
also
lower
success
avoid
intub
predict
mark
reduct
respiratori
rate
supplement
oxygen
requir
within
hour
niv
complic
revers
infect
document
among
health
care
worker
care
sar
patient
niv
high
air
chang
initi
eight
later
per
hour
unidirect
neg
pressur
ventil
environ
patient
improv
within
day
niv
continu
deterior
niv
contraind
endotrach
intub
mechan
ventil
consid
emphasis
endotrach
intub
procedur
high
infect
risk
staff
involv
must
adher
stringent
infect
control
measur
must
strictli
adher
centr
adopt
ventilatori
strategi
similar
recommend
ard
caus
tidal
volum
kept
low
mlkg
predict
bodi
weight
plateau
pressur
maintain
cm
h
higher
risk
barotrauma
sar
mani
patient
suffer
sever
ill
outbreak
sar
also
present
wide
spectrum
sever
minor
patient
mild
respiratori
ill
recov
either
without
specif
form
treatment
antibiot
therapi
alon
four
sporad
case
guangzhou
decemb
januari
belong
categori
major
patient
definit
epidemiolog
link
microbiolog
confirm
may
prudent
administ
antivir
agent
kaletra
ribavirin
interferon
soon
sar
diagnos
effect
antivir
agent
may
decreas
sever
subsequ
immunopatholog
damag
thu
need
salvag
therapi
immunosuppress
patient
enter
immunopatholog
phase
immunomodulatori
agent
like
indic
optim
choic
dosag
durat
therapi
known
retrospect
experi
suggest
dosag
may
titrat
accord
diseas
sever
suffici
larg
dosag
given
longer
durat
may
requir
sever
case
puls
methylprednisolon
may
effect
rescu
therapi
case
unsatisfactori
respons
recurr
respiratori
failur
initi
respons
respons
remain
poor
despit
treatment
immunoglobulin
form
treatment
may
tri
assist
ventil
form
niv
institut
earli
clinic
cours
complic
signific
respiratori
failur
respons
remain
poor
hour
elect
intub
consid
earli
ampl
time
avail
institut
infect
control
measur
manag
airway
highli
infecti
diseas
fever
recur
later
cours
sar
treatment
clinic
pictur
may
easili
distinguish
superimpos
bacteri
even
fungal
sepsi
empir
antipseudomon
antibiot
would
usual
indic
consid
patient
would
put
immunomodulatori
agent
time
clinic
respons
still
appar
opportunist
infect
reason
exclud
higher
dosag
methylprednisolon
consid
puls
sar
rescu
eg
mp
g
day
especi
given
previous
patient
respond
fever
subsid
improv
chest
radiograph
oxygen
satur
chest
radiograph
may
slightli
lag
behind
clinic
improv
featur
per
se
may
warrant
use
addit
steroid
radiolog
infiltr
usual
improv
gradual
despit
reduc
dosag
corticosteroid
next
week
howev
small
proport
critic
sar
patient
cours
relentless
intens
care
unit
mortal
could
chapter
review
pathogenesi
variou
treatment
modal
treatment
principl
sar
subsequ
unpreced
collabor
effort
among
medic
research
commun
worldwid
alreadi
gain
larg
amount
knowledg
novel
viru
within
short
space
year
howev
random
control
treatment
trial
remain
perform
improv
understand
optim
treatment
new
diseas
